Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX™], a biodegradable polymeric drug conjugate: Characterization, preclinical pharmacology, and preliminary clinical data

Advances in Experimental Medicine and Biology

Volumn 519, Issue , 2003, Pages 81-99

  Singer, Jack W ^a   Baker, Brian ^a   De Vries, Peter ^a   Kumar, Anil ^a   Shaffer, Scott ^a   Vawter, Ed ^a   Bolton, Mary ^a   Garzone, Pamela ^a  

^a Cell Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL DERIVATIVE; PACLITAXEL POLIGLUMEX; POLYGLUTAMIC ACID; POLYGLUTAMIC ACID PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; BIODEGRADABILITY; CARCINOMA; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PACLITAXEL; POLYGLUTAMIC ACID; TAXOIDS;

ANIMALIA;

EID: 0037619168     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (32)

1. Maeda, H. 2001. The enhanced permeability and retention (EPR) effect in tumour vasculature: the key role of tumour-selective macromolecular drug targeting. Adv. Enzyme Regul. 41:189-207.
2. Maeda, H., J. Wu, T. Sawa, Y. Matsumura, and K. Hori. 2000. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release 65:271-284.
3. Matsumura, Y. and H. Maeda. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392.
4. Pimm, M. V., A. C. Perkins, J. Strohalm, K. Ulbrich, and R. Duncan. 1996. Gamma scintigraphy of the biodistribution of 123I-labelled n-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J Drug Targeting 3:375-383.
5. Vasey, P. A., S. B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A. H. Thomson, L. S. Murray, T. E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, and J. Cassidy. 1999. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5:83-94.
6. McCormick-Thomson, L. A. and R. Duncan. 1989. Poly(amino acid) copolymers as a potential soluble drug delivery system. 1. pinocytic uptake and lysosomal degradation measured in vitro. J Bioactive and Compatible Polymers 4:242-251.
7. Duncan, R. 1992. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3:175-210.
8. Duncan, R. and F. Spreafico. 1994. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27:290-306.
9. Gueritte-Voegelein, F., D. Guenard, F. Lavelle, M. T. Le Goff, L. Mangatal, and P. Potier. 1991. Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem. 34:992-998.
10. Li, C., D. F. Yu, R. A. Newman, F. Cabral, L. C. Stephens, N. Hunter, L. Milas, and S. Wallace. 1998. Complete regression of well-established tumours using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res 58:2404-2409.
11. Li, C., Price, J. E., Milas, L., Hunter, N. R., Ke, S., Yu, D. F., Chusilp, C., and Wallace, S. Antitumor activity of Poly(L-glutamic acid)-Paclitaxel on syngeneic and xenografted tumours. Proc Am Assoc Cancer Res 40, 1909. 1999.
12. Li, C., R. A. Newman, Q. P. Wu, S. Ke, W. Chen, T. Hutto, Z. Kan, M. D. Brannan, C. Charnsangavej, and S. Wallace. 2000. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumour. Cancer Chemother. Pharmacol. 46:416-422.
13. de Vries, P., Kumar, A., Heasley, E., and Singer, J. W. Optimisation of the anti-tumour activity of water-soluble poly L-glutamic acid (PG)-paclitaxel (TXL) conjugates. AACR - NCI - EORTC 92, 451. 11-17-1999. Washington DC.
14. Singer, J. W., de Vries, P., Kumar, A., Baker, B., Lynn, S., Li, C., and Wallace, S. Poly-L-Glutamic Acid Paclitaxel Conjugate (PG-TXL): A water-soluble biodegradable conjugate with decreased toxicity and enhanced efficacy. 4th International Symposium on Polymer Therapeutics. 2000.
15. Baker, B., Bellamy, G., Nudelman, E., Shaffer, S., de Vries, P., Heasley, E., Stone, I., Reigh, C., Burke, S., Kumar, A., Klein, P., Brannan, M., and Singer, J. W. Biodistribution of poly-L-glutamic acid-paclitaxel (CT-2103), and paclitaxel in C57BL/6 mice bearing subcutaneous B16 melanomas. Cancer Research. 2001.
16. Shaffer, S. A., Baker Lee, C., Nudelman, E., Kumar, A., Coon, M., Stone, I., de Vries, P., and Singer, J. Metabolism of poly-L-glutamic acid (PG) paclitaxel (CT-2103); proteolysis by lysosomal cathepsin B and identification of intermediate metabolites. Proc Amer Assoc Cancer Res. 2002.
17. Shaffer, S., Baker Lee, C., de Vries, P., Bellamy, G., Heasley, E., Stone, I., Kumar, A., Bhatt, R., Nudelman, E., Reigh, C., Baker, B., and Singer, J. In vivo identification of monoglutamyl paclitaxel metabolite from poly-L-glutamic acid-paclitaxel (CT-2103) in tumour bearing mice. Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics, A010970. 2001.
18. Li, C., J. E. Price, L. Milas, N. R. Hunter, S. Ke, D. F. Yu, C. Chusilp, and S. Wallace. 1999. Antitumor activity of Poly(L-glutamic acid)-Paclitaxel on syngeneic and xenografted tumours. Clin Cancer Res 5:891-897.
19. CTI. Investigator Brochure CT-2103. 2001.
20. + human colon carcinoma cell line xenografts compared to free TXL. Proc Am Assoc Cancer Res 42, 462. 2001.
21. Li, C., S. Ke, Q. Wu, W. Tansey, N. Hunter, L. M. Buchmiller, L. Milas, C. Charnsangavej, and S. Wallace. 2000. Potentiation of ovarian OCa-1 tumour radioresponse by poly (L-glutamic acid)-paclitaxel conjugate. Int.J Radiat.Oncol.Biol.Phys. 48:1119-1126.
22. Li, C., S. Ke, Q. Wu, W. Tansey, N. Hunter, L. Buchmiller, L. Milas, C. Charnsangavej, and S. Wallace. 2000. Tumour irradiation enhances the specific-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 6:2829-2834.
23. Ke, S., Oldham, E., Milas, L., Hunter, N. R., Tansey, W., Charnsangavej, C., Wallace, S., and Li, C. Schedule-independent radiosensitization of a murine ovarian OCa-1 tumour by PG-TXL. Proc Am Assoc Cancer Res 40, 4223. 1999.
24. Li, C., Ke, S., Oldham, E., Milas, L., Hunter, N. R., Tansey, W., Charnsagavej, C., and Wallace, S. Enhancement of tumour radioresponse of a murine ovarian carcinoma by poly(L-glutamic acid)-paclitaxel conjugate. Ninth International Symposium on Recent Advances in Drug Delivery Systems. 1999.
25. Mason, K. A., Hunter, N., Wallace, S., and Milas, L. Poly (L-glutamic Acid)-paclitaxel dramatically enhances the anti-tumour efficacy of radiotherapy. AACR - NCI - EORTC, 397. 2001. Miami Beach, Florida.
26. Cavaletti, G., E. Cavalletti, P. Montaguti, N. Oggioni, O. De Negri, and G. Tredici. 1997. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18:137-145.
27. Cavaletti, G., G. Tredici, M. Braga, and S. Tazzari. 1995. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp. Neurol. 133:64-72.
28. Kadota, T., H. Chikazawa, H. Kondoh, K. Ishikawa, S. Kawano, K. Kuroyanagi, N. Hattori, K. Sakakura, S. Koizumi, E. Hiraiwa, and. 1994. [Toxicity studies of paclitaxel. (II) - One-month intermittent intravenous toxicity in rats]. J. Toxicol. Sci. 19 Suppl 1:11-34.
29. Kadota, T., H. Chikazawa, H. Kondoh, K. Ishikawa, S. Kawano, K. Kuroyanagi, N. Hattori, K. Sakakura, S. Koizumi, E. Hiraiwa, and. 1994. [Toxicity studies of paclitaxel. (I) - Single dose intravenous toxicity in rats]. J. Toxicol. Sci. 19 Suppl 1:1-9.
30. Todd, R., Sludden, J., Boddy, A. V., Griffin, M. J., Robson, L., Cassidy, J., Bissett, D., Main, M., Brannan, M. D., Elliott, S., Fishwick, K., Verrill, M., and Calvert, H. Phase I and pharmacological study of CT-2103, a poly (L-glutamic Acid)-paclitaxel conjugate. Journal of Clinical Oncology, #439. 2001.
31. Bolton, M. G., Cassidy, J., and Calvert, H. Phase I studies of PG-Paclitaxel (CT-2103) as a single agent and in combination with cisplatin. 5th International Symposium on Polymer Therapeutics. 2002.
32. Sludden, J., Boddy, A. V., Griffin, M. J., Robson, L., Todd, R., Cassidy, J., Bissett, D., Main, M., Brannan, M. D., Elliott, S., Verrill, M., and Calvert, H. Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate. Proc Amer Assoc Cancer Res 42, 535. 2002.